AstraZeneca India appoints Dr. Sanjeev Panchal as Country President & MD
Sanjeev is currently the Country President for AstraZeneca Malaysia
Sanjeev is currently the Country President for AstraZeneca Malaysia
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Acquisition expands Merck’s growing hematology portfolio
The approval further strengthens the Potassium Chloride franchise for the company.
The company is focussed on increasing the capacity utilizations while controlling costs
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Subscribe To Our Newsletter & Stay Updated